Abbott Previews Presentations Of Its Products At Forthcoming ACS Meeting

In short

Abbott has adopted the clever strategy of announcing its schedule of key presentations at the American College of Cardiology’s (ACC) 61st Annual Scientific Session and i2 Summit 2012, to be held March 24 – 27 in Chicago.

Background

Presentations will include;

  • Data on patients at high surgical risk treated with the investigational MitraClip® system, an innovative catheter-based device for mitral valve repair;
  • Two-year clinical results on the investigational Absorb™ bioresorbable vascular scaffold (BVS), a novel device designed to restore blood flow to the heart and then dissolve, leaving the patient with a vessel free of a permanent metallic implant.
  • A number of presentations on Abbott’s XIENCE V® Everolimus Eluting Coronary Stent System;
  • Preliminary results from a unique pilot program that screens women for cardiovascular risk factors at obstetrics/gynecology clinics.

Company comments 

“Abbott has achieved worldwide vascular leadership by developing innovative products to advance patient care, such as the XIENCE family of drug eluting stents. XIENCE is the world’s leading drug eluting stent and continues to gain market share in the U.S. and internationally – supported by a consistent stent design and solid clinical data from more than 100 clinical trials,” said Robert B. Hance, senior vice president, vascular, Abbott. “We continue to strengthen our leadership position with first-of-their-kind technologies such as the MitraClip system and the Absorb bioresorbable vascular scaffold – two devices with the potential to have a significant impact on patient care. We look forward to presenting new data for these important technologies at the upcoming ACC meeting.”

Regulatory status of Abbott’s products

In the United States, the MitraClip system is limited to investigational use only and is not available for sale. The MitraClip system is currently under review for approval by the U.S. Food and Drug Administration. The MitraClip system received CE Mark in 2008 and is authorized for sale in Europe and other international markets.

In the United States, Absorb is an investigational device and is not available for sale. Absorb has CE Mark and is authorized for sale in Europe.

XIENCE PRIME received CE Mark in 2009 and FDA approval in 2011, and is now available in the U.S., Europe, the Middle East and most of Asia. The XIENCE V drug eluting stent is approved and marketed in the U.S., Europe, Japan and other international markets.

The full schedule including timings can be found on the company’s press release here.

Source: Abbott